← boardnext 2026-09
AVIR
Atea Pharmaceuticals, Inc.distress 4/10 · elevated risk$4.74-1%today-23% from 52w high
Nephrology 1
Lead: Healthy Volunteer Study
Revenue
pre-revenue
Liquidity
$79M
Runway
0.5 yrs
Shares 1y
+1%
Price & events
+29.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.5%
1D
+0.5%
1W
+5.8%
1M
-14.1%
3M
+15.0%
6M
+35.8%
1Y
+22.8%
2Y
-81.1%
5Y
-88.6%
All
Overview
- Market Cap
- $379.33M
- Volume
- 17.20K
- 52 Week Range
- $2.82 – $6.15
- Total Shares
- 80.03M
- Float Shares
- 60.05M
- Short %
- 11.27%
- % Held by Insiders
- 13.40%
- % Held by Institutions
- 80.12%
- RVOL
- 0.05x
- Beta
- 0.32
Pipeline stages · 5 programs
Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Buprenorphine/Naloxone, BEM/RZR, Methadone
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Ethinyl Estradioll/Levonorgestrel (EE/LNG), Bemnifosbuvir/Ruzasvir (BEM/RZR)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Digoxin vs Digoxin, BEM/RZR vs Digoxin, 2h BEM/RZR
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting, Treatment B-Omeprazole 20 mg
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 7 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-09 Estimated 50% readout ~2026-11-15 | Phase 3 | Bemnifosbuvir-Ruzasvir (BEM/RZR), Sofosbuvir-Velpatasvir (SOF/VEL) | HEPATITIS C VIRUS CHRONIC INFECTION | — | active not recruiting |
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 3 | Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir | HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C | — | active not recruiting |
| 2026-06 | Phase 1 | Buprenorphine/Naloxone, BEM/RZR, Methadone | Healthy Volunteer Study | 32 | recruiting |
| 2026-05 | Phase 1 | Bemnifosbuvir (BEM)/Ruzasvir (RZR) as a fixed-dose combination | Healthy Volunteer Study, Hepatic Impairment, Renal Impairment | 28 | recruiting |
| 2026-02-17 | Phase 1 | Ethinyl Estradioll/Levonorgestrel (EE/LNG), Bemnifosbuvir/Ruzasvir (BEM/RZR) | Healthy Volunteer Study | 24 | completed |
Show all 7 trials · 2 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-07-02 | Phase 1 | Digoxin vs Digoxin, BEM/RZR vs Digoxin, 2h BEM/RZR | Healthy Volunteer Study | 38 | completed |
| 2025-06-28 | Phase 1 | Treatment A-Bemnifosbuvir/Ruzasvir FDC administered fasting, Treatment B-Omeprazole 20 mg | Healthy Volunteer Study | 20 | completed |
Catalyst news & presentations · 2
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-03-31withdrawalDriver Opportunity Partners III withdrew nomination of J. Abbott R. Cooper for election to board.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $9 (+83% upside) · 3 analysts
- 2026-03-09Evercore ISI GroupOutperform
- 2025-04-11Morgan StanleyEqual-Weight
- 2024-08-13Morgan StanleyUnderweight → Equal-Weight
Competitors — Healthy Volunteer Study
Recent news
- 2026-07-15Atea Pharmaceuticals (AVIR) Faces Modest Decline Near Key Support Level - Ichimoku Kumo Twist - dars.gov.et
- 2026-07-14Atea begins phase 1 trial of hepatitis E treatment AT-587 - Investing.com UK
- 2026-07-14Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus - GlobeNewswire
- 2026-07-14Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus - GlobeNewswire
- 2026-07-14Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus - GlobeNewswire
- 2026-07-14Hepatitis E Has No Approved Treatments as Atea Begins Human Trial - Stock Titan
- 2026-07-14Atea Pharmaceuticals Initiates First-in-Human Phase 1 Clinical Trial of AT-587 for the Treatment of Hepatitis E Virus - GlobeNewswire
- 2026-07-10Atea Pharmaceuticals (AVIR) Q1 2026 earnings summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.